Profound Medical Corp. Files 8-K
Ticker: PROF · Form: 8-K · Filed: Nov 28, 2025 · CIK: 1628808
| Field | Detail |
|---|---|
| Company | Profound Medical Corp. (PROF) |
| Form Type | 8-K |
| Filed Date | Nov 28, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, filing
TL;DR
Profound Medical Corp. filed a standard 8-K on 11/28/25, no major news.
AI Summary
Profound Medical Corp. filed an 8-K on November 28, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by Profound Medical Corp., without disclosing new material events or financial performance details.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- Profound Medical Corp. (company) — Registrant
- November 28, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Profound Medical Corp.?
The primary purpose is for Regulation FD Disclosure and to file Financial Statements and Exhibits, as indicated by the Item Information section.
On what date was this 8-K report filed or effective?
The report was filed as of November 28, 2025.
What is the principal executive office address for Profound Medical Corp.?
The principal executive offices are located at 2400 Skymark Avenue, Unit 6, Mississauga, Ontario, Canada L4W 5K5.
What is the SIC code for Profound Medical Corp.?
The Standard Industrial Classification (SIC) code is 3841, for Surgical & Medical Instruments & Apparatus.
Does this filing announce any new products or significant financial results?
This filing does not appear to announce new products or significant financial results; it is primarily for routine disclosures and exhibits.
Filing Stats: 548 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-11-28 13:55:55
Filing Documents
- f8k_112825.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 12KB
- 0001171843-25-007654.txt ( ) — 226KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_112825_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On November 28, 2025, Profound Medical Corp. (the "Company") issued a press release announcing that it will launch its TULSA-AI Volume Reduction module at the Radiological Society of North America meeting taking place in Chicago on November 30, 2025 through December 4, 2025. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated November 28, 2025 104 Cover Page Interactive Data File (embedded within Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROFOUND MEDICAL CORP. Date: November 28, 2025 By: /s/ Rashed Dewan Rashed Dewan Chief Financial Officer